CSIMarket Company Name, Ticker, Competitors, else..


Biocryst Pharmaceuticals Inc   (NASDAQ: BCRX)
Other Ticker:  
 

Biocryst Pharmaceuticals Inc

BCRX's Fundamental analysis



Looking into Biocryst Pharmaceuticals Inc growth rates, revenue grew by 56.89 % in the first quarter of 2025 from the same quarter a year ago. Ranking at No. 485

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 10.32 %

Biocryst Pharmaceuticals Inc realized net income compared to net loss a year ago in first quarter of 2025

• More on BCRX's Growth


Biocryst Pharmaceuticals Inc
realized a net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 104.36 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.3.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.87.


• More on BCRX's Valuation
 
 Total Debt (Millions $) 315
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 2,555,761
 Net Income/Employee (TTM) $ -271,421
 Receivable Turnover (TTM) 6.42
 Tangible Book Value (Per Share $) -2.10

Biocryst Pharmaceuticals Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 104.36 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.3.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.87.


• More on BCRX's Valuation

•  Market Capitalization (Millions $) 2,166
•  Shares Outstanding (Millions) 215
•  Employees 197
•  Revenues (TTM) (Millions $) 503
•  Net Income (TTM) (Millions $) -53
•  Cash Flow (TTM) (Millions $) 21
•  Capital Exp. (TTM) (Millions $) -1
•  Total Debt (Millions $) 315
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 2,555,761
•  Net Income/Employee(TTM) $ -271,421
•  Receivable Turnover Ratio (TTM) 6.42
•  Tangible Book Value (Per Share $) -2.10

•  Market Capitalization (Millions $) 2,166
•  Shares Outstanding (Millions) 215
•  Employees 197
•  Revenues (TTM) (Millions $) 503
•  Net Income (TTM) (Millions $) -53
•  Cash Flow (TTM) (Millions $) 21
•  Capital Exp. (TTM) (Millions $) -1


    BCRX's Profitability Comparisons
Biocryst Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 14.59 %.

Biocryst Pharmaceuticals Inc net profit margin of 0.02 % is currently ranking no. 15 in Biotechnology & Pharmaceuticals industry, ranking no. 141 in Healthcare sector and number 1638 in S&P 500.


Profitability by Segment
Total 0.02 %



  Ratio
•   Capital Ratio (MRQ) 2.93
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 1.04
•  Inventory Turnover Ratio (TTM) 3.3



Biocryst Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 14.59 %.

Biocryst Pharmaceuticals Inc net profit margin of 0.02 % is currently ranking no. 15 in Biotechnology & Pharmaceuticals industry, ranking no. 141 in Healthcare sector and number 1638 in S&P 500.

• More on BCRX's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com